ICU Medical reports Q3 2026 earnings beat and raises outlook toward high end of guidance
ICU Medical posted third‑quarter 2026 revenue of roughly $560 million, beating forecasts, and reported adjusted earnings per share of $2.44, surpassing analyst estimates. Net income was about $26.8 million, and adjusted gross margin expanded to around 42%. CEO Vivek Jain said the company will finish the year near the top of its adjusted EBITDA range of $415‑$435 million and EPS range of $8.60‑$9, while lowering its capital‑spending plan to $75 million and continuing debt reduction.
Why it matters
The company’s guidance near the high end of its ranges suggests stronger profitability than previously expected, which may support a higher valuation. Continued debt repayment and a reduced capital‑spending forecast improve cash‑flow outlook, potentially benefiting shareholders and debt holders.
Key facts
- 1Q3 2026 revenue was $560.4 million, beating estimates by 1.5%. finance.yahoo.com
- 2Adjusted earnings per share for the quarter were $2.44. finance.yahoo.com
- 3Net income for the quarter was $26.8 million, or $1.07 per share. finance.yahoo.com
- 4Adjusted gross margin was about 42%, up roughly one percentage point from the prior quarter. finance.yahoo.com
- 5Vital Care revenue fell 12% on a reported basis and 10% organically. finance.yahoo.com
- 6Third‑quarter free cash flow was $83 million and the company repaid $80 million of debt, leaving $1.16 billion in debt at quarter end. finance.yahoo.com
Open questions
- Revenue figure differs between $560.4 million and $556 million.
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.